What To Know
- (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, was selected as one of five companies in Massachusetts to receive a START Stage 2 award from MassVentures, which funds deep tech startups based in Massachusetts as they advance technology developed under SBIR/STTR grant funding.
- This $200,000 START Stage 2 award will enable late-stage development activities on MyoRegulator®, and follows a $100,000 START Stage 1 award funded in 2022.
PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, was selected as one of five companies in Massachusetts to receive a START Stage 2 award from MassVentures, which funds deep tech startups based in Massachusetts as they advance technology developed under SBIR/STTR grant funding. This START Stage 2 funding was awarded on the basis of PathMaker’s $4.9M NIH grant from the NINDS CREATE Devices program to develop MyoRegulator®, a first-in-class, non-invasive neuromodulation device for treating spasticity and related neuronal hyperexcitability disorders.
“We are grateful for the Stage 2 award from MassVentures as we work to bring MyoRegulator® to market,” said Nader Yaghoubi, M.D., Ph.D., Co-Founder and Chief Executive Officer of PathMaker. “As we continue our US multi-center pivotal trial in post-stroke spasticity and work to launch our first clinical trial in ALS this year, MassVentures support for late-stage development of our product is greatly appreciated.”
MassVentures is a venture capital firm that helps transfer research and early-stage innovations into technology businesses and jobs in Massachusetts. The MassVentures START program helps deep tech startups convert their Small Business Innovation and Small Business Technology Transfer research (SBIR/STTR) into businesses and jobs in Massachusetts. This $200,000 START Stage 2 award will enable late-stage development activities on MyoRegulator®, and follows a $100,000 START Stage 1 award funded in 2022.